Monte Rosa Therapeutics (GLUE) stock
GLUE's Quality Score fell 1 point on Mon, Oct 5, to -7. Its volume eased back to normal.
Follow GLUE's trial news. Pro members can get an alert when Monte Rosa Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What's next for GLUE, and how long its cash lasts
From Monte Rosa Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
$90.1M in cash
Dilution on the horizon
- Shelf registration (S-3ASR, filed Feb 11, 2026)
- At-the-market share sales program (S-3ASR, filed Feb 11, 2026)
Insiders
CEO Markus Warmuth sold 9,500 shares on Jul 16. 29 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 55% in 3 months, 29% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 14% over the same 3 months.
−2Growth sales down 84% on the year, operating margin down 641.4 points
5 more things pulling GLUE's score down, for Pro members
What's next
Expected to report Thu Nov 5, before the open
After its last 4 reports it closed +0.4% on average, higher 2 of 4 times.
What would turn GLUE's score around: 9 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Nothing is firing on GLUE right now
One per group is shown here.
Also on the chart
- RSI 1422.5
- MACD (12, 26, 9)Below signal
- 50-day average$14.56
- 200-day average$18.15
- ADX 1438.4
- Support$8.94
- Resistance$11.47
- Bollinger Bands (20, 2)Inside
- Volume1.4x
How GLUE ranks in Biotech
GLUE is #285 of 300 by Quality Score. The top three are shown with their scores, and more by name.
ONC8/1420
RGEN8/1420
CORT8/1418
GENBOpen for its score
GILDOpen for its score
GOSSOpen for its score
GPCROpen for its score
GLUE0/14-7
When does GLUE report earnings, and what happens after?
Expected to report Thu Nov 5, before the open (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026Before open | Before open | +0.1% | +0.6% | +2.2% |
| May 7, 2026Before open | Before open | -0.7% | -2.8% | -7.0% |
| Mar 17, 2026Before open | Before open | -1.3% | -2.0% | -8.1% |
| Nov 6, 2025Before open | Before open | +0.7% | +5.7% | +15.0% |
Who is trading GLUE
GLUE insider trades
2 insiders sold $451K across 2 filings in the last 6 months. No open-market buys on record. The newest:
About Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of GLUE's score, with the points and the reason
- All 14 checks on GLUE and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on GLUE
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.